Deutsche Bank
ACAD icon

Deutsche Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

Deutsche Bank’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-825
Closed -$22K – 5259
2019
Q1 		$22K Buy
+825
New +$19.3K ﹤0.01% 4769
2017
Q1 		– Sell
-600
Closed -$17K – 4872
2016
Q4 		$17K Buy
600
+300
+100% +$7.94K ﹤0.01% 4623
2016
Q3 		$9K Buy
+300
New +$10.2K ﹤0.01% 4680

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Deutsche Bank's ACAD Position: Q1 2026 in Review

Deutsche Bank increased its Acadia Pharmaceuticals (ACAD) stake by 1.4% in Q1 2026, buying an estimated $282K and bringing the position to 840,414 shares worth $18.7M. The position accounts for 0.01% of the portfolio, ranked #868.

Deutsche Bank first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $56M in Q4 2020. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Deutsche Bank held 840,414 shares of Acadia Pharmaceuticals worth $18.7M as of Q1 2026.
  • Deutsche Bank bought 11,820 Acadia Pharmaceuticals shares in Q1 2026, an estimated $282K.
  • Acadia Pharmaceuticals made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #868 holding.
  • Deutsche Bank first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Deutsche Bank's Acadia Pharmaceuticals position peaked at $56M in Q4 2020.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.